中國海洋發展(08047.HK)2021財年盈轉虧至3.78億港元
格隆匯6月29日丨中國海洋發展(08047.HK)公佈,截至2021年3月31日止年度,客户合約收益6.2億港元,同比下降24.78%; 年度公司股權持有人應占虧損約為港幣3.78億元,而2020年為溢利約港幣2802.9萬元。因COVID-19對差旅施加限制,差旅及交通開支大幅降低以及集團實施節約成措施以及精簡行政程序作出部份抵銷。行政開支主要組成部份是職工和董事的薪金和福利;租金和差餉,法律和專業費用及折舊。基本每股虧損8.57港仙。
集團繼續發展與其中國業務夥伴及潛在夥伴的業務關係以增加及探尋新的收入來源。集團於年度繼續專注於水產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.